Intersection of mechanisms of type 2AVWD through defects in VWF multimerization, secretion,ADAMTS-13 susceptibility, and regulated storage

Blood

Volumn 119, Issue 19, 2012, Pages 4543-4553

  Jacobi, Paula M ^a,b   Gill, Joan Cox ^a,c   Flood, Veronica H ^a,c   Jakab, David A ^a   Friedman, Kenneth D ^a,c   Haberichter, Sandra L ^a,c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Children's Hospital of Wisconsin ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; POLYMER; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; HUMAN; HUMAN CELL; MUTATION; PHENOTYPE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 2A; WEIBEL PALADE BODY; WILD TYPE;

EID: 84861068515     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-360875     Document Type: Article

References (44)

1. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A. 1974; 71(5):1906-1909.
2. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982;95(1):355-360. (Pubitemid 13208536)
3. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNAencodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5(8): 1839-1847.
4. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
5. Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood. 1987;69(1):27-32. (Pubitemid 17007071)
6. Voorberg J, Fontijn R, van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von willebrand factor (vWF): multimerization is independent of dimerization. EMBO J. 1990;9(3):797-803.
7. Titani K, Kumar S, Takio K et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25(11):3171-3184. (Pubitemid 16056960)
8. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83(12):3536-3544. (Pubitemid 24175543)
9. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem. 1992;267(13):8723-8731.
10. Wise RJ, Barr PJ, Wong PA, Kiefer MC, Brake AJ, Kaufman RJ. Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. Proc Natl Acad Sci U S A. 1990;87(23):9378-9382. (Pubitemid 120030629)
11. Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood. 2005;105(1):145-152. (Pubitemid 40053076)
12. Cramer EM, Meyer D, le MR, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood. 1985;66(3):710-713. (Pubitemid 15230782)
13. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, RosenthalW, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000; 106(1):107-116. (Pubitemid 30437246)
14. Haberichter SL, Montgomery RR. Structure and Function of von Willebrand Factor. In: Coleman, Marder, Hirsch, Clowes, George, eds. Hemostasis and Thrombosis-Basic Principles and Clinical Practice. 5th Ed. Philadelphia, PA: Lippincott, Williams, Wilkins; 2006:707-722.
15. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114. (Pubitemid 44403432)
16. Eikenboom JC, Matsushita T, Reitsma PH et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood. 1996;88(7):2433-2441. (Pubitemid 26327491)
17. Rosenberg JB, Haberichter SL, Jozwiak MA et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood. 2002;100(5):1699-1706. (Pubitemid 34925147)
18. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997;76(1):1-20.
19. Holmberg L, Nilsson IM. von Willebrand's disease. Eur J Haematol. 1992;48(3):127-141.
20. Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160-174. (Pubitemid 30601459)
21. Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103(6):2032-2038. (Pubitemid 38326217)
22. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992;267(7):4424-4430.
23. Englender T, Lattuada A, Mannucci PM, Sadler JE, Inbal A. Analysis of Arg834Gln and Val902Glu type 2Avon Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics. Blood. 1996;87(7):2788-2794. (Pubitemid 26102228)
24. Hassenpflug WA, Budde U, Obser T et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood. 2006;107(6):2339-2345. (Pubitemid 43345553)
25. Hillery CA, Mancuso DJ, Evan SJ et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin-but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood. 1998;91(5):1572-1581. (Pubitemid 28110321)
26. Haberichter SL, Allmann AM, Jozwiak MA, Montgomery RR, Gill JC. Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage. J Thromb Haemost. 2009;7(4):641-650.
27. Haberichter SL, Fahs SA, Montgomery RR. von Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood. 2000;96(5):1808-1815. (Pubitemid 30661065)
28. Flood VH, Gill JC, Morateck PA et al. Gain-offunction GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011;117(6):e67-e74.
29. Haberichter SL, Budde U, Obser T, Schneppenheim S, Wermes C, Schneppenheim R. The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. Blood. 2010; 115(22):4580-4587.
30. Michaux G, Hewlett LJ, Messenger SL et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood. 2003;102(7): 2452-2458. (Pubitemid 37193582)
31. Nichols WC, Lyons SE, Harrison JS, Cody RL, Ginsburg D. Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis. Proc Natl Acad Sci U S A. 1991;88(9):3857-3861. (Pubitemid 21916723)
32. Castaman G, Missiaglia E, Federici AB, Schneppenheim R, Rodeghiero F. An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation. Thromb Haemost. 2000;84(2):350-351. (Pubitemid 30601486)
33. Kashiwagi T, Matsushita T, Ito Y et al. L1503R is a member of group I mutation and has dominantnegative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease. Haemophilia. 2008; 14(3):556-563. (Pubitemid 351638744)
34. Berber E, James PD, Hough C, Lillicrap D. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution. J Thromb Haemost. 2009;7(10):1672-1679.
35. Hommais A, Stepanian A, Fressinaud E et al. Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion. J Thromb Haemost. 2006;4(1):148-157.
36. Castaman G, Giacomelli SH, Jacobi P et al. Homozygous type 2 N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype. J Thromb Haemost. 2010;8(9):2011-2016.
37. Haberichter SL, Jacobi P, Montgomery RR. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage. Blood. 2003;101(4):1384-1391. (Pubitemid 36182510)
38. Huang RH, Wang Y, Roth R et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A. 2008;105(2):482-487. (Pubitemid 351171734)
39. Schneppenheim R, Michiels JJ, Obser T et al. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. Blood. 2010;115(23):4894-4901.
40. Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost. 2004;2(2): 257-265. (Pubitemid 40186039)
41. Purvis AR, Gross J, Dang LT et al. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc Natl Acad Sci U S A. 2007;104(40):15647-15652. (Pubitemid 350035354)
42. Bowen DJ, Collins PW, Lester W et al. The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. Br J Haematol. 2005;128(6):830-836. (Pubitemid 40444877)
43. Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood. 2004;103(3):941-947. (Pubitemid 38129554)
44. Bodó I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood. 2001;98(10):2973-2979.